

January 2025

## DMX-1001 (oral noribogaine) is a potential breakthrough treatment for alcohol use disorder (AUD)

### MANAGEMENT

#### Deborah Mash, Ph.D.

*Chief Executive Officer, President, and Founder*

World-renowned expert in addiction treatment and the discovery of noribogaine, has dedicated her career to pioneering research in the field, securing FDA approval for clinical trials and founding companies to advance the development of medications for substance use disorders.

#### Mark Ellison, Ph.D.

*Chief Development Officer and President of Clinical Operations*

Proven track record of driving start-ups and small pharma companies towards successful product development and market launch, notably contributing to the development of life-saving products in the opioid crisis while holding key positions at highly regarded organizations in the industry.

#### E. Douglas Kramer, M.D.

*Vice President of Clinical and Regulatory Affairs*

Highly experienced medical professional with a proven track record in drug development, regulatory affairs, and addiction treatment, having served as a Medical Officer at the FDA and advancing the clinical development of various pharmaceutical products throughout his career.

#### John C. Thomas Jr.

*Treasurer, Chief Financial Officer, and Secretary*

30+ years of experience as a CFO in the biotechnology and medical device industries, with a proven track record of success in both public and private companies.

### SUMMARY

DemeRx, Inc. a clinical-stage biopharmaceutical company at the forefront of addiction therapeutics, is developing DMX-1001 (oral noribogaine), an investigational neuroplastogen for alcohol use disorder (AUD). DMX-1001 promotes neuroplasticity, a process that enables the brain to rewire neural circuits disrupted by chronic heavy drinking. and mitigate cravings, compulsive behavior, and the risk of relapse associated with AUD.

### KEY POINTS

- **Targeting AUD where need is high.** Alcohol use disorder is a chronic brain disorder characterized by uncontrolled heavy drinking that impacts over 29 million people and is a leading cause of preventable death in the United States. Less than 5% use medication for AUD.
- **Robust potential for the right product.** While naltrexone, acamprosate and disulfiram have been available for AUD patients for many years, the condition is still one of significant unmet need. At least 60% of those treated for AUD will relapse to hazardous drinking within six months.
- **DMX-1001 approach in AUD has advantages.** DMX-1001 is a shift from current pharmacological approaches for AUD that brings two circuit level mechanisms into one novel candidate with the following characteristics:
  1. **Affects multiple CNS circuits.**  
DMX-1001 engages multiple neurotransmitters within the addiction circuitry of the brain to reset chemical imbalances.
  2. **Potential to stimulate neuronal repair.**  
Modulates neuroplasticity to enhance dopamine pathways that could support recovery of brain regions affected by alcohol and drug misuse.
  3. **Potential to work quickly with lasting effect.**  
DMX-1001 demonstrated promising efficacy in animal models of AUD.
  4. **Favorable side effect profile.**  
In clinical Phase 1 and preclinical trials, noribogaine was well tolerated with no euphoric effects or potential for abuse.
  5. **Multifaceted substance disorder treatment.**  
Preclinical findings indicate noribogaine's potential in addressing opioid and cocaine dependencies.
- **Solid intellectual property around DMX-1001.** DemeRx has built extensive IP around noribogaine including 49 US patents.
- **Phase 1b trial data expected Q12025.** Current Phase 1b in healthy volunteers is to determine PK, PD and safety of DMX-1001 for Phase 2 trial in AUD.

For more information:  
[www.demrx.com](http://www.demrx.com)

Vitaly Pirotsky | Investor Enquiries  
[vpirotsky@demrx.com](mailto:vpirotsky@demrx.com) | +1.804.502.2552